Veness Adam M 4

What Happened

• Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics (DNTH), was granted a derivative equity award covering 100,000 shares on Feb 3, 2026. The grant is reported at an acquisition price of $0.00 (i.e., no cash paid at grant) and is recorded as a derivative instrument (stock option award).

Key Details

• Transaction date: 2026-02-03. Form 4 filed: 2026-02-04 (timely under Form 4 rules).
• Transaction type/code: Award/Grant (A) — derivative equity award.
• Amount: 100,000 shares; reported price $0.00; reported value $0 (derivative).
• Vesting: Shares underlying the award vest in equal monthly installments over four years beginning Jan 1, 2026, subject to continued service (per footnote).
• Shares owned following the transaction: not specified in the provided filing excerpt.
• No indication of an immediate sale or cashless exercise — this is a time‑based grant, not a disposition.

Context

• This is a stock option/derivative award that will vest over time; until each tranche vests the underlying shares are typically not owned and may be forfeited if the reporting person leaves the company. Such grants are common for employee retention and do not by themselves indicate the insider is buying or selling stock on market.